There are many tactics for overshadowing bad news, but one of the most effective is to make even bigger news. AstraZeneca PLC succeeded on that front April 26 as the news that CEO and Board Member David Brennan was resigning, effective June 1, distracted many away from the reality of the multinational pharma's poor first-quarter financial performance.
Following on the heels of several late-stage drug-development setbacks in recent months and a looming patent cliff that threatens several...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?